Compare TOMZ & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | CTXR |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 19.8M |
| IPO Year | N/A | N/A |
| Metric | TOMZ | CTXR |
|---|---|---|
| Price | $0.80 | $1.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $6.00 |
| AVG Volume (30 Days) | 22.5K | ★ 576.4K |
| Earning Date | 11-14-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,688,341.00 | N/A |
| Revenue This Year | $18.31 | N/A |
| Revenue Next Year | $103.30 | $731.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $0.65 |
| 52 Week High | $1.50 | $5.95 |
| Indicator | TOMZ | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 58.45 |
| Support Level | $0.76 | $0.97 |
| Resistance Level | $0.85 | $1.54 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 43.48 | 81.49 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.